Literature DB >> 27714625

Drug utilization study of systemic antifungal agents in a Brazilian tertiary care hospital.

Maria Clara Padovani de Souza1, Andrezza Gouvêa Dos Santos2, Adriano Max Moreira Reis3.   

Abstract

Background The inappropriate use of systemic antifungal agents can result in unnecessary exposure, adverse events, increased microbial resistance and increased costs. Aim This study analysed the use of systemic antifungal agents and adherence to treatment guidelines for fungal infections. Setting A Brazilian tertiary hospital. Methods This cross-sectional study investigated 183 patients who were treated with systemic antifungals. Antifungal drugs were classified according to the fourth level of the Anatomical Therapeutic Chemical classification system. The appropriateness of treatments was analysed with respect to the indication, dose and potential drug-drug interactions. Descriptive and univariate statistical analyses were performed. The main outcome measure was the frequency of adherence to treatment guidelines for fungal infections. Results The number of established treatments was 320, with 163 (50.9 %) pre-emptive, 63 (19.7 %) targeted, 56 (17.5 %) empirical and 38 (11.9 %) prophylactic treatments. The overall adherence to the treatment guidelines was 29.4 %. The proportion of appropriate treatment considering indication, dosage and drug-drug interactions was 84.1, 67.8 and 47.2 %, respectively. The most commonly prescribed systemic antifungal agents were fluconazole in 170 (53.1 %), voriconazole in 43 (13.4 %) and amphotericin B deoxycholate in 36 (11.3 %) cases. Conclusion The study showed a low proportion of appropriate antifungal drug use; the dosage and drug-drug interactions criteria were the determining factors for the high percentage of non-adherence to treatment guidelines in the hospital. The profile of antifungal agents used showed the predominance of fluconazole as well as the use of new antifungal drugs.

Entities:  

Keywords:  Drug interactions; Drug therapy; Invasive fungal infection; Systemic antifungal

Mesh:

Substances:

Year:  2016        PMID: 27714625     DOI: 10.1007/s11096-016-0382-6

Source DB:  PubMed          Journal:  Int J Clin Pharm


  30 in total

1.  Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America.

Authors:  Thomas J Walsh; Elias J Anaissie; David W Denning; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; Brahm H Segal; William J Steinbach; David A Stevens; Jo-Anne van Burik; John R Wingard; Thomas F Patterson
Journal:  Clin Infect Dis       Date:  2008-02-01       Impact factor: 9.079

2.  Use of antifungal agents in pediatric and adult high-risk areas.

Authors:  E Ramírez; J García-Rodríguez; A M Borobia; J M Ortega; S Lei; A Barrios-Fernández; M Sánchez; A J Carcas; A Herrero; J M de la Puente; J Frías
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-07-01       Impact factor: 3.267

3.  Antifungal therapy in European hospitals: data from the ESAC point-prevalence surveys 2008 and 2009.

Authors:  P Zarb; B Amadeo; A Muller; N Drapier; V Vankerckhoven; P Davey; H Goossens
Journal:  Clin Microbiol Infect       Date:  2012-07-24       Impact factor: 8.067

4.  Evaluation of antifungals in the surgical intensive care unit: a multi-institutional study.

Authors:  Kevin W Garey; Melinda M Neuhauser; David T Bearden; Joan P Cannon; Russell E Lewis; Layne O Gentry; Dimitrios P Kontoyiannis
Journal:  Mycoses       Date:  2006-05       Impact factor: 4.377

5.  Antifungal stewardship in a tertiary-care institution: a bedside intervention.

Authors:  M Valerio; P Muñoz; C G Rodríguez; B Caliz; B Padilla; A Fernández-Cruz; M Sánchez-Somolinos; P Gijón; J Peral; J Gayoso; I Frias; M Salcedo; M Sanjurjo; E Bouza
Journal:  Clin Microbiol Infect       Date:  2015-01-23       Impact factor: 8.067

6.  Prevalence and clinical significance of potential drug-drug interaction in hematopoietic stem cell transplantation.

Authors:  Danilo D Trevisan; Juliana B Silva; Henrique C Oliveira; Silvia R Secoli; Maria Helena M Lima
Journal:  Cancer Chemother Pharmacol       Date:  2014-12-27       Impact factor: 3.333

7.  European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3--2009 update.

Authors:  J Maertens; O Marchetti; R Herbrecht; O A Cornely; U Flückiger; P Frêre; B Gachot; W J Heinz; C Lass-Flörl; P Ribaud; A Thiebaut; C Cordonnier
Journal:  Bone Marrow Transplant       Date:  2010-07-26       Impact factor: 5.483

8.  Inadequacy of fluconazole dosing in patients with candidemia based on Infectious Diseases Society of America (IDSA) guidelines.

Authors:  Kevin W Garey; Manjunath P Pai; Katie J Suda; Robin S Turpin; Milind D Rege; Dana E Mingo; David T Bearden
Journal:  Pharmacoepidemiol Drug Saf       Date:  2007-08       Impact factor: 2.890

Review 9.  Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents.

Authors:  Roger J M Brüggemann; Jan-Willem C Alffenaar; Nicole M A Blijlevens; Eliane M Billaud; Jos G W Kosterink; Paul E Verweij; David M Burger
Journal:  Clin Infect Dis       Date:  2009-05-15       Impact factor: 9.079

10.  Utilization of fluconazole in an intensive care unit at a university hospital in Brazil.

Authors:  Tânia Pereira Salci; Marina Gimenes; Carlos Aparecido dos Santos; Terezinha Inez Estivalet Svidzinski; Silvana Martins Caparroz-Assef
Journal:  Int J Clin Pharm       Date:  2012-11-28
View more
  2 in total

1.  Evaluation of Candida bloodstream infection and antifungal utilization in a tertiary care hospital.

Authors:  Tatiana Aporta Marins; Alexandre R Marra; Michael B Edmond; Marines Dalla Valle Martino; Paula Kiyomi Onaga Yokota; Ana Carolina Cintra Nunes Mafra; Marcelino Souza Durão Junior
Journal:  BMC Infect Dis       Date:  2018-04-18       Impact factor: 3.090

2.  Appropriateness of antifungal prescribing in Oman.

Authors:  Fatima Issa El-Hussain; Abdullah Balkhair; Ibrahim Al-Zakwani; Mohammed Al Za'abi
Journal:  Pharm Pract (Granada)       Date:  2022-01-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.